The protection of Carrageenan induced

The % protection of Carrageenan induced paw edema in rat was treated with phenylbutazone guggulosomes. The rats were treated with optimized formulation F3 of prepared guggulosomes. The controlled and treated rats were observed for 0.5, 1, 2, 3 & 4 h on plethysmometer and anti-inflammatory effect was determined by paw volume of rat, thus the reading obtained by percent edema inhibition at certain interval of time was 62 ± 0.0057, 79 ± 0.015, 82 ± 0.0057, 88 ± 0.0208 & 92 ± 0.208% of control and 58 ± 0.0057, 64 ± 0.0305, 71 ± 0.0264 and 85 ± 0.0115 & 87 ± 0.532% for treated. The results revealed that there were higher percent protection in phenylbutazone loaded guggulosomes and provides desired anti-inflammatory effect and percent edema inhibition was shown in (Fig. 7). The optimizations of physical and chemical stability are required in guggulosomes. The stability of vesicles is one of the major problems in the formulation of guggulosomes because of leaching and drug accumulation from the Afatinib core and lipid layers[26,27]. The results of physical stability of optimized formulation F3 in various intervals of time are shown in (Table 4). guggulosomal suspension was divided into two batches and kept in sealed vials (10 ml) at refrigerator temperature 4 ± 2°C/60± 5% RH and room temperature 25 ± 2°C/60± 5% RH. The study was held as the function of time as 7, 15, 30, 60 and 90 days of storage. Then the guggulosomal suspension was directly sonicated for 15 s in bath sonicator and characterized for size, zeta potential and encapsulation efficiency. The triplicate analysis was done for a concordance reading and the results are reported as mean ± SD. The guggulosomes were kept in RT confirmed significant increase in particle size (from 287.2  ±  1.41 nm after 7 days 289  ± 1.07 nm) and decrease in percent entrapment efficiency from 60.80 ± 0.707 to 59.95 ± 2.642. This was allied with significant increase in PDI from less than 0.226 ± 0.19 to 0.573 ± 0.47 and diminishing zeta potential from about −35.7to −34.8 mV. These are signs of particle accumulation and leakage of the encapsulated drug. After 7 days the RT samples had too much aggregation with increasing in particle size 302  ± 1.26, 355.46  ± 0.14, 364.46  ± 2.73, 384.52  ± 1.63 nm with decrease in % encapsulation efficiency 58.86 ± 1.201, 58.80 ± 1.532, 55.46 ± 1.223, 54.21 ± 1.016 after 15, 30, 60 and 90 days respectively. This result also supported by the increasing value of PDI 0.591 ± 0.05, 0.625 ± 0.72, 0.640 ± 1.20, 0.664 ± 0.11 with decreasing value of zeta potential −32.5, −30.4, −29.7, and −27.4respectively. In comparison, the guggulosomes stored at 4 °C were quite stable as there was minimum increase in size; PDI and decrease in zeta potentials and encapsulation efficiency after storage of 90 days were observed. The optimized storage condition for guggulosomes formulation F3 was found to be stable at 4 ± 2 °C/60± 5% RH. The response surface models fit between the factors and measured responses are shown in the following polynomial equations:where, GL = Guggul Lipid; CH = Cholesterol. The response surface plots representing the relationship between the studied factors and measured responses is demonstrated in (Fig. 8).
Conclusion
Declaration of interest
Acknowledgment
Introduction The Eudragit® range of polymers, like the versatile acrylic material Plexiglas (introduced in 1933), grew out of Dr. Rohm’s deep knowledge of acrylic acid and its derivatives. In the year 1954 first two polymers Eudragit L and Eudragit S for enteric coating were launched. It offered a synthetic polymer for film-coating of improved quality than materials such as sugar and shellac. Eudragit based products for rapidly disintegrating and sustained release coatings were added during the 1960s, expanding the widening potential applications considerably. The introduction of aqueous polymer dispersion forms of Eudragit in 1972 was a major milestone, making the process of coating easier, safer, more versatile and economical. With the development of various grades of Eudragit, it became possible to handle many aspects of formulation development such as film coating, granulation, direct compression, melt extrusion and mastery of technologies to engineer immediate or sustained release, as well as GI targeting, enteric coatings, pulsed release and transdermal formulations. Hence Eudragit a versatile polymer for drug delivery was selected for extensive review.